phrykt

Kyverna Therapeutics, Inc. (KYTX): who owns it and who trades it

As of Nov 16, 2026, KYTX insiders reported 1 open-market sale worth $293K and 1 purchase worth $1000K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Karen Marie Walker (Chief Technology Officer), with $293K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Kyverna Therapeutics

From the latest filings

Overall: about as much buying as selling. Funds, insiders and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns KYTX

120 funds and institutions reported KYTX shares worth $338M at the end of Q2 2026, about 63% of the company. The largest holder is GordonMD Global Investments LP with 7.0%.

Funds and institutions (13F) 63%Everyone else 37%

10 largest owners, by share of the company

GordonMD Global Investments LP7.0%
Gilead Sciences, Inc.6.8%
BlackRock, Inc.5.2%
Bain Capital Life Sciences Investors, LLC4.8%
AIGH Capital Management LLC4.6%
Deerfield Management Company, L.P.3.3%
Vanguard Capital Management LLC3.1%
T. Rowe Price Associates2.0%
Geode Capital Management, LLC1.7%
Insight Holdings Group, LLC1.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
GordonMD Global Investments LP4.24M7.02%$37.8MNo change
Gilead Sciences, Inc.4.13M6.83%$36.8MNo change
BlackRock, Inc.3.13M5.19%$27.9M+257%
Bain Capital Life Sciences Investors, LLC2.88M4.77%$25.7M-7%
AIGH Capital Management LLC2.80M4.63%$24.9M+40%
Deerfield Management Company, L.P.2.00M3.31%$17.8MNo change
Vanguard Capital Management LLC1.90M3.14%$16.9M+6%
T. Rowe Price Associates1.19M1.96%$10.6M-24%
Geode Capital Management, LLC1.05M1.74%$9.4M+148%
Insight Holdings Group, LLC989,0541.64%$8.8MNo change
Morgan Stanley982,3071.63%$8.8M+1%
State Street Corp982,2331.63%$8.8M+610%
Propel Bio Management, LLC883,1981.46%$7.9M+37%
Woodline Partners LP845,3251.40%$7.5MNo change
Millennium Management LLC639,7801.06%$5.7M-36%
Mbb Public Markets I LLC614,4771.02%$5.5MNo change
Adage Capital Partners Gp, L.l.c.500,0000.83%$4.5MNo change
D. E. Shaw & Co., Inc.469,3460.78%$4.2M-35%
Wells Fargo & Company373,0090.62%$3.3M+226%
UBS Group AG365,5740.60%$3.3M-19%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, KYTX insiders reported $1000K of open-market purchases and $293K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$1000K
1 trades, 1 people
Sales, 12 months
$293K
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Dec 18, 2025
Filed Dec 22, 2025

Purchases and sales by month

$1000K$1000KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Dec 18, 2025Beth C SeidenbergDirectorPurchase133,333$7.50$1000KForm 4
Dec 15, 2025Karen Marie WalkerChief Technology OfficerSale23,998$12.20$293KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Beth C SeidenbergDirector$1000K–Dec 18, 2025
Karen Marie WalkerChief Technology Officer–$293KDec 15, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

KYTX short interest

High short interest. 14.7% of KYTX shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 72%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 9.10M KYTX shares were sold short, 14.7% of the shares outstanding, down 4.7% from the report before. At the average daily volume of 784,251 shares, buying them all back would take about 11.6 trading days (days to cover).

Shares short, % of all shares

14.7%May 15Oct 3016.6%

Days to cover

11.6May 15Oct 3014.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269.10M14.71%-5%784,25111.6
Oct 15, 20269.54M15.43%-1%909,74610.5
Sep 30, 20269.62M15.55%+10%1.09M8.8
Sep 15, 20268.77M14.18%+4%812,83910.8
Aug 31, 20268.45M13.67%-1%684,63412.3
Aug 14, 20268.50M13.74%+4%636,88813.3
Jul 31, 20268.18M13.53%+4%937,1178.7
Jul 15, 20267.85M12.98%+9%1.30M6.0
Jun 30, 20267.22M11.94%+19%1.58M4.6
Jun 15, 20266.07M10.04%+6%720,9188.4
May 29, 20265.74M9.50%+9%837,7546.8
May 15, 20265.28M8.74%+2%858,6356.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Kyverna Therapeutics company events

Kyverna Therapeutics filed 18 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Sep 24, 2026.

  1. Sep 24, 2026AnnouncementShared information with investors. Filing
  2. Aug 11, 2026ResultsReleased financial results. Filing
  3. Jul 27, 2026AgreementAs previously disclosed, on July 22, 2023, Kyverna Therapeutics, Inc. entered into that certain Development and Manufacturing Services Agreement (as amended by Amendment #1 thereto on July 24, 2023, the “Prior Agreement”) with ElevateBio Basecamp, Inc., pursuant to which ElevateBio has provided the… Filing
  4. Jul 9, 2026AgreementAs previously disclosed, on October 31, 2025, Kyverna Therapeutics, Inc. entered into that certain Loan and Security Agreement with Oxford Finance LLC, as collateral agent, and certain lenders from time to time party thereto. Filing
  5. Jun 2, 2026VoteReported shareholder vote results. Filing
  6. May 18, 2026LeadershipThe Board of Directors of Kyverna Therapeutics, Inc. appointed Gregory Martini as the Company’s Chief Financial Officer, effective May 18, 2026. Filing
  7. May 12, 2026ResultsReleased financial results. Filing
  8. May 4, 2026AnnouncementKyverna Therapeutics, Inc. issued a press release announcing the appointment of Nadia Dac as the Company’s Chief Commercial Officer, effective May 4, 2026. Filing
  9. Apr 22, 2026AnnouncementShared information with investors. Filing
  10. Apr 22, 2026AnnouncementShared information with investors. Filing
  11. Apr 20, 2026AnnouncementShared information with investors. Filing
  12. Mar 26, 2026ResultsReleased financial results. Filing
  13. Feb 24, 2026LeadershipThe board of directors of Kyverna Therapeutics, Inc. appointed Andrew Miller, Ph.D. as a Class III director of the Company, effective immediately. Filing
  14. Feb 3, 2026LeadershipKaren Walker notified Kyverna Therapeutics, Inc. that she will be retiring from the Company and will cease to serve as the Company’s Chief Technology Officer, effective February 9, 2026. Filing
  15. Jan 12, 2026LeadershipThe Board appointed Christi Shaw, a current member of the Board, as the Company’s Executive Chairperson of the Board, effective January 12, 2026. Filing
  16. Dec 18, 2025AgreementKyverna Therapeutics, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Leerink Partners LLC and Morgan Stanley & Co. LLC as the representatives of the several underwriters named therein, relating to the issuance and sale in an underwritten public offering of an aggregate… Filing
  17. Dec 15, 2025AnnouncementShared information with investors. Filing
  18. Dec 15, 2025AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Kyverna Therapeutics financials

Famous investors that hold KYTX

4 of the 50 well-known investors we track reported holding KYTX in their latest 13F filing. The largest position is Israel Englander's, worth $5.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026826,137$5.6M0.0%+29%
Jim Simons · Renaissance TechnologiesQ3 2026327,821$2.2M0.0%-2%
Steve Cohen · Point72 Asset ManagementQ3 2026186,902$1.3M0.0%New
Ken Griffin · Citadel AdvisorsQ3 2026137,034$932K0.0%-7%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named KYTX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026GordonMD Global Investments LP13G/A7.3%
Nov 16, 2026GordonMD Global Investments LP13G/A7.3%
Oct 19, 2026Orin Hirschman13G5.9%
Oct 19, 2026Orin Hirschman13G5.9%

Questions about Kyverna Therapeutics, Inc. (KYTX) stock

Who owns the most KYTX stock?

The largest reported owner of Kyverna Therapeutics, Inc. (KYTX) is GordonMD Global Investments LP, with 7.0% of the company. In total, 120 funds and institutions reported holding KYTX at the end of Q2 2026, together about 63% of the shares. See the largest owners.

Are KYTX insiders buying or selling?

In the last 12 months, KYTX insiders reported 1 open-market purchase worth $1000K and 1 sale worth $293K. The latest trade was on Dec 18, 2025. See every trade.

What is the short interest in KYTX?

As of Oct 30, 2026, 9.10M KYTX shares were sold short, 14.7% of the shares outstanding, down 4.7% from the report before. At the average daily volume of 784,251 shares, buying them all back would take about 11.6 trading days (days to cover). See the history.

Which famous investors hold KYTX?

4 of the 50 well-known investors we track reported KYTX in their latest 13F filing, including Israel Englander, Jim Simons, Steve Cohen. The largest position is worth $5.6M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.